Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06728059 · ClinicalTrials.gov registry record · NA
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
A NA study of Type 1 Diabetes, sponsored by Sue Brown.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06728059: Recruiting NA study of Type 1 Diabetes, sponsored by Sue Brown.
NCT06728059 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Sue Brown. The registered enrollment target is 16 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06728059, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Sue Brown.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS\_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.
Primary Outcome
CGM-measured time in range (TIR, 70-180 mg/dL) during the 18-hour hotel sessions on AIDANET or AIDANET+BPS\_RL. The time periods begin at 6 PM and end at noon on the next day, thereby covering two meals - dinner and breakfast.
Conditions Studied
Interventions
- DEVICE Automated Insulin Delivery Adaptive NETwork (AIDANET)
- DEVICE AIDANET+ BPS_RL→AIDANET
Study Locations (1)
Virginia
- University of Virginia Center for Diabetes Technology - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-02-05 |
| Est. Completion | 2025-07-31 |
| Phase | NA |
What NCT06728059 shows while recruiting
NCT06728059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Automated Insulin Delivery Adaptive NETwork (AIDANET) is the first listed.
NCT06728059 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06728059 about?
NCT06728059 is a clinical study titled "Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm". A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS\_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.
What is the current status of trial NCT06728059?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-02-05. Estimated completion is 2025-07-31.
What conditions does trial NCT06728059 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06728059?
The interventions under investigation include: Automated Insulin Delivery Adaptive NETwork (AIDANET) (DEVICE), AIDANET+ BPS_RL→AIDANET (DEVICE).
Who is sponsoring clinical trial NCT06728059?
This trial is sponsored by Sue Brown, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06728059 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06728059's enrollment target sits among peer trials
16 162nd of 198 higher than 34 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI